The consistent late-stage program wins (seven in seven months) suggest strong customer demand and revenue visibility for Lifecore's CDMO services. Monitor upcoming quarterly filings for revenue recognition from these contracts and any new customer announcements. The neurology product win adds diversification to the pipeline.
Price Chart
Executive Summary
Lifecore Biomedical announced a new commercial manufacturing agreement with an unnamed global pharmaceutical company for an injectable neurology product. This marks the seventh late-stage program win in seven months, signaling strong business development momentum for the CDMO.
Key Facts
- New agreement with a global pharma company for tech transfer and commercial manufacturing of an injectable suspension product for neurological disorders
- Seventh late-stage program win in the last seven months
- Product is a higher-viscosity suspension formulation requiring specialized manufacturing expertise
- Contract is with an undisclosed global pharmaceutical company (counterparty name not disclosed)
Financial Impact
Revenue contribution and contract value not disclosed; seven late-stage wins in seven months indicate accelerating commercial pipeline growth
Risk Factors
- Counterparty and deal financial terms undisclosed, making revenue impact unclear
- Late-stage programs may not all reach commercial launch if customers fail to obtain regulatory approval
- Customer concentration risk if agreements are with a small number of large pharma partners
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311684 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $4.44 $4.74 | ▲ +6.76% | ▲ +7.36% | $6.53 (+47.07%) |
Jul 2, 2026 13w ago | 8-K | $5.09 $4.36 | ▲ +14.34% | ▲ +13.93% | $6.53 (−28.29%) |
Jun 15, 2026 15w ago | Press Release | $5.49 $4.63 | ▼ −15.66% | ▼ −14.91% | $6.53 (+18.94%) |
Jun 5, 2026 17w ago | 8-K | $5.57 $5.05 | ▼ −9.34% | ▼ −10.97% | $6.53 (+17.24%) |
Jun 2, 2026 17w ago | Press Release | $5.45 $5.27 | ▼ −3.30% | ▼ −1.74% | $6.53 (+19.82%) |
May 6, 2026 21w ago | 8-K | $4.96 $5.67 | ▼ −14.31% | ▼ −11.53% | $6.53 (−31.65%) |
Mar 26, 2026 27w ago | Press Release | $3.87 $5.02 | ▲ +29.72% | ▲ +19.05% | $6.53 (+68.73%) |
Mar 16, 2026 28w ago | Press Release | $4.37 $5.20 | ▲ +18.99% | ▲ +15.21% | $6.53 (+49.43%) |
Mar 4, 2026 30w ago | Press Release | $7.02 $3.84 | ▼ −45.30% | ▼ −41.51% | $6.53 (−6.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access